Early test for new Weight-Loss shot begins
NCT ID NCT07313761
Summary
This early-stage study aims to understand how the body absorbs two different versions of an experimental drug called AMG 133, which is being developed for weight management. It will involve about 340 adults who are living with overweight or obesity. The main goal is to compare how the drug moves through the body when given as two slightly different injections, while also checking for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anaheim Clinical Trials
RECRUITINGAnaheim, California, 92801-2658, United States
-
CenExel Collaborative Neuroscience Research, LLC Los Alamitos
RECRUITINGLos Alamitos, California, 90720, United States
-
Clinical Pharmacology Of Miami, LLC
RECRUITINGMiami, Florida, 33172-3161, United States
-
Ohio Clinical Trials, Inc.
RECRUITINGColumbus, Ohio, 43212, United States
Conditions
Explore the condition pages connected to this study.